RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation
Authors:
Open Access
- 5 July 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (9) , 4161-4170
Abstract
Oestrogen receptor ɑ (ERɑ) is overexpressed in two‐thirds of all breast cancers and involves in development and breast cancer progression. Although ERɑ‐positive breast cancer could be effective treated by endocrine therapy, the endocrine resistance is still an urgent clinical problem. Thus, further understanding of the underlying mechanisms ERɑ signalling is critical in dealing with endocrine resistance in breast cancer patients. MCF‐7 and T47D breast cancer cell lines are used to carry out the molecular biological experiments. Western blot is used to assess the relative protein level of ERɑ, RNF168 and actin. Real‐time PCR is used the measure the relative ERɑ‐related gene mRNA level. Luciferase assay is used to measure the relative ERɑ signalling activity. Chromatin immunoprecipitation is used to measure the RNF168 binding affinity to ERɑ promoter regions. WST assay and flow cytometry are used to measure the cell proliferation capacity. We use Student's t test and one‐way ANOVA test for statistical data analysis. Here, we report an important role in ERɑ‐positive breast cancer cells for RNF168 protein in supporting cell proliferation by driving the transcription of ERɑ. RNF168 is highly expressed in breast cancer samples, compared with normal breast tissue. In patients with breast cancer, RNF168 expression level is correlated with poor endocrine treatment outcome. Depletion of RNF168 causes decreased cell proliferation in MCF‐7 and T47D cells. Besides, depletion RNF168 reduced mRNA level of ERɑ and its target genes, such as PS2 and GREB1. Chromatin immunoprecipitation revealed that ERɑ transcription is associated with RNF168 recruitment to ERɑ promoter region, suggesting that transcriptional regulation is one mechanism by which RNF168 regulates ERɑ mRNA level and ERɑ signalling in breast cancer cells. RNF168 is required for ERɑ‐positive breast cancer cell proliferation and facilitate ERɑ signalling activity possibly through promoting transcription of ERɑ.Keywords
Funding Information
- National Science Foundation (8170110153)
- Foundation of Henan Educational Committee (17A310025)
This publication has 35 references indexed in Scilit:
- Estrogen receptor beta in breast cancerMolecular and Cellular Endocrinology, 2014
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor ProgressionJournal of Clinical Oncology, 2012
- HECT and RING finger families of E3 ubiquitin ligases at a glanceJournal of Cell Science, 2012
- BRCA1 Regulates Acetylation and Ubiquitination of Estrogen Receptor-αMolecular Endocrinology, 2010
- The RNF8/RNF168 ubiquitin ligase cascade facilitates class switch recombinationProceedings of the National Academy of Sciences, 2009
- Estrogen signaling pathway and its imaging in human breast cancerCancer Science, 2009
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- RNF168, a new RING finger, MIU-containing protein that modifies chromatin by ubiquitination of histones H2A and H2AXBMC Molecular Biology, 2009
- Minireview: Genomic Organization of the Human ER Gene Promoter RegionMolecular Endocrinology, 2001
- Role of direct interaction in BRCA1 inhibition of estrogen receptor activityOncogene, 2001